10 dRUg diSCOvERy & dEvELOpMEnT
Market focuses on high-speed,
high-reproducibility arrays
E
ach year, Frost & Sullivan gives a advanced genomics, regenerative medicine,
Competition is fierce in
company of the year award that diagnostics, forensics, and environmental testing.
the high-speed array recognises outstanding management, For example, Life Technologies is building on its
market as 2009 sees consistent growth, and the ability to leading position in the capillary electrophoresis
a whole raft of new
offer high quality products and/or services as well sequencing market by making a major play
technologies launched
as have a positive social and economic impact on in next generation sequencing. By leveraging
onto the market. Sean
local and national communities. The award also its Invitrogen brand of nucleic acid sample
Ottewell reports.
highlights exceptional customer service offerings preparation technologies and Applied Biosystems
and the expertise to take advantage of market brand SOLiD System for ultra-high throughput
La concurrence est
changes by capturing and solidifying market DNA sequencing, Life Technologies is expected
féroce sur le marché des
presence, or execute of innovative strategies to have a major role in bringing next generation
analyses simultanées à within the existing competitive landscape. sequencing to the medical realm.
grande vitesse alors que
Based on its recent analysis of the drug However, the company’s high-speed TagMan
2009 est le théâtre du
discovery technologies market, this year’s OpenArray technology is facing fierce competition
lancement commercial
recipient of the North American Frost & Sullivan as other manufacturers launch their latest array
de toute une série de
company of the year award is Life Technologies. systems.
nouvelles technologies.
Un reportage de Sean
Formed from the combination of Invitrogen One such company is Synbiosis, a
Ottewell.
and Applied Biosystems, Life Technologies is on a world-leading manufacturer of automated
clear path to become its own unique organisation microbiological systems. The company has
with unparalleled efficiency and speed of announced that its ProtoCOL automatic zone
Angesichts der Tatsache, operation. More importantly, the reengineered measuring system has new features, designed
das für 2009 eine ganze
Life Technologies promises extraordinary revenue to improve the speed of analysing single radial
Reihe neuer Technologien
growth that far outpaces the performance of its immunodiffusion (SRD) plates.
für den Markt angekündigt
two predecessor companies. The ProtoCOL can generate results from a 16-
wurden, hat sich ein
starker Marktwettbewerb
“Prior to the 2008 merger, Applied Biosystems zone SRD plate of flu vaccines in minutes. This
entwickelt. Ein Bericht
held the largest percentage of market share means scientists can analyse ten SRD plates in
von Sean Ottewell.
in the microRNA, PCR reagents, capillary the time it would take to manually analyse one
electrophoresis sequencing, qRT-PCR, and life (Fig. 1).
sciences mass spectrometry markets,
while Invitrogen held the largest
percentage of market share in the cell
culture and protein expression and
purification markets,” explains Jonathan
Witonsky, Industry Manager, Drug
Discovery & Clinical Diagnostics, Frost &
Sullivan. “By merging, the new company,
Life Technologies, holds a significant
market share in nine additional market
segments, including the nucleic acid
purification and isolation market, the
laboratory information management
systems market, the cell-based assays
market, the research ELISA market, the
high content screening market, the liquid
chromatography market, the protein
electrophoresis market, the RNAi market,
and the proteomics array market.”
F&W says that a US$300 million
investment in research and development Fig. 1. With ProtoCOL scientists can analyse 10 SRD
is likely to expand the company’s position plates in the time it would take to manually analyse
in the burgeoning markets surrounding one.
www.scientistlive.com
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44